Pfizer announced Tuesday that its oral pill can help protect those at high risk of severe COVID-19.
Pfizer said that the pill should work against the Omicron variant, citing data from lab studies.
"Final data available from all high-risk patients … confirmed prior results of interim analysis showing PAXLOVID reduced risk of hospitalization or death by 89% (within three days of symptom onset) and 88% (within five days of symptom onset) compared to placebo; no deaths compared to placebo in non-hospitalized, high-risk adults with COVID-19," the statement said.
This story is developing. Please check back for updates.
Read the original article on Business Insider